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1. Introduction
Generally, disease susceptibility is determined based on changes not only in DNA sequen‐
ces but also in the activities of genes and chromosomal regions. Epigenetic regulation has
attracted attention as a mechanism underlying changes of activities of genes and chromoso‐
mal regions. Epigenetic modification regulates gene activity and is essential for cell division
and histogenesis. Genetically, phenotype diversity of identical cells is thought to be caused
by differences in epigenetic profiles. Epimutations have also recently been recognized as the
first step of tumorigenesis of cancers and are thought to be direct dispositions to cancers [1].
2. What is epimutation?
Epimutation affects one or both alleles and decreases the gene product by inhibiting tran‐
scription. Tumor cells are typical examples of the results of epimutation that occurs at a high
frequency in mammals. Epimutation in cancer generally occurs in somatic cells with tumor
progression. Various epimutations are present in cancers and are frequently observed in tu‐
mor suppressor genes [1-4].
Germline epimutation which occurs in germ cells is defined as those changes maintained in
fertilization and embryogenesis and present in all somatic cells in the mature body. Trans‐
mission of epigenetic characteristics through generations has been reported. The cancer risk
is similar in individuals carrying a germline epimutation. However, epimutation is not nec‐
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essarily inherited, and inheritance patterns that do not follow Mendel’s laws have been re‐
ported [5-8]. Complete elimination of epimutation in spermatogenesis has also been shown
[9]. Only inheritance of maternal epimutation has been confirmed, suggesting that elimina‐
tion of epimutation in oogenesis is less likely to occur [8-9]. Several genomic imprinting-as‐
sociated somatic cell abnormalities are thought to be caused by germline epimutation [4].
Constitutional epimutation is defined as those changes observed in all tissues in the body
due to occurrence in an early step of embryogenesis before differentiation into the three
germ layers. Not all cells possess this type of epimutation, leading to a mosaic pattern at the
cell level, and it is unclear if this epimutation is transmitted from the previous generation.
All epimutation types are a first step leading to tumorigenesis and may be direct causes of
carcinogenesis [1].
3. Germline epimutation and disease
Epimutation is not only involved in cancer, but is also observed in genomic imprinting (Ta‐
ble 1). Since a gene transmitted from one parent is selectively expressed in genomic imprint‐
ing, a hereditary disease develops when the gene is defective, even though the allelic gene is
normal. The characteristic phenotype of genomic imprinting is maintained by imprinting
control centers (ICs). ICs are short sequences present in the gene to be imprinted. Hemiallel‐
ic methylation of ICs results in transcription of the other allele, controlling imprinting [1].
Diverse gene aberrations in these ICs, such as micro defects, have been discovered, and
these are considered to be the causes of epimutations observed in very rare neurobehavioral
congenital familial diseases such as Angelman syndrome (AS), Prader-Willi syndrome
(PWS), and Beckwith-Wiedemann syndrome (BWS). PWS is characterized by hypotonia in
the neonatal period, increased appetite, overeating and subsequent obesity after infancy,
characteristic desires, mild mental retardation, and hypoplasia of the external genitalia. In
contrast, AS is characterized by severe mental retardation, epilepsy, and awkward move‐
ment. However, the causative genetic locus is located in the q11-q13 region on the long arm
of chromosome 15 in both diseases. PWS and AS are caused by chromosomal 15q11q13 dele‐
tion in many cases, but there are a few cases of imprinting mutation causing abnormal ge‐
nomic imprinting. In imprinting mutation, the parental chromosome is normal, but the
imprinting of 15q11-q13 is changed to the opposite pattern. Familial cases of imprinting mu‐
tations are known, and minute deletions upstream of the SNURF-SNRPN gene, which has
ICs in PWS and AS, have been described [10]. However, ICs are resistant to minute changes
or contain several extra elements, and most imprinting mutations are thought to occur due
to epimutation after fertilization [11].
BWS is a congenital disease with a high reported risk of embryonal fetal tumors, such as
Wilms tumor, hepatoblastoma, and rhabdomyosarcoma. The p15.5 region on the short arm of
chromosome 11 (11p15.5) has been identified as the causative locus. There are two imprinting
domains in 11p15.5: the Cyclin-dependent kinase inhibitor 1C/KCNQ1 opposite antisense transcript
1(CDKN1C/KCNQ1OT1) domain and the Insulin-like growth factor 2(IGF2)/H19 domain, and
expression of the imprinting gene near the domain is controlled by the respective imprinting
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regulation region. CDKN1C  expression is decreased due to DNA hypomethylation of the
CDKN1C/KCNQ1OT1  domain in about 30-50% of BWS cases, and IGF2  expression is en‐
hanced due to DNA hypermethylation of the IGF2/H19 domain in about 5-10% [12]. Silver-
Russell syndrome (SRS) is characterized by intrauterine growth restriction and severe failure
to thrive after birth, and epimutation of the H19 gene in 11p15.5 is the cause of this disease
[13]. IGF2 and H19 are regulated by a common enhancer present in the terminal end of the
short arm of chromosome 11. Normally, sperm-derived H19–DMR is methylated and ovum-
derived H19–DMR is not methylated. The enhancer acts on IGF2 because CTCF protein can‐
not bind to methylated DMR in the former case, whereas it acts on H19 because CTCF protein
binds to non-methylated DMR in the latter. Hypomethylation of sperm-derived H19-DMR
due to epimutation causes the gene to behave similarly to the maternal domain and induces
underexpression of IGF2 and overexpression of H19, causing SRS due to IGF2 underexpres‐
sion [14]. Thus, these diseases are thought to develop due to aberration in ICs.
Gene name Epimutation type Disease
hMLH1 germline, constitutional Lynch syndrome
hMSH2 germline Lynch syndrome
DAPK1 unknown B-cell CLL
HBA2 unknown α-Thalassemia
BRCA2 constitutional Sporadic breast cancer
KIP2/LIT1 unknown Beckwith-Wiedemann syndrome
IGF2 unknown Beckwith-Wiedemann syndrome
H19 unknown Silver-Russell syndrome
Table 1. Epimutation and disease
Epimutation also occurs due to genomic changes, such as insertion, deletion, and changes in
the length of tandem repeat sequences, which are termed copy number variations (CNVs)
[15]. In α-thalassemia, another well-known epimutation-associated disease, the deleted re‐
gion of the LUC7-like (LUC7L) gene is close to an α-globin gene, hemoglobin alpha 2 (HBA2),
leading to methylation of the HBA2 gene promoter [16].
4. Epimutation of DNA mismatch repair genes
A study on familial cancer showed that a gene group inactivated by mutation in characteris‐
tic regions produces a predisposition to cancer. Mutation of a tumor suppressor gene, Reti‐
noblastoma (RB), provided the first evidence of a causative gene in hereditary cancer [17].
Subsequently, Nishishou et al. reported mutation of Adenomatous polyposis coli (APC) in fam‐
ilial adenomatous polyposis [17] and Hussussian et al. found mutation of Cyclin-dependent
kinase inhibitor2A (CDKN2A) in familial melanoma [19]. As more mutations have been iden‐
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tified in tumor suppressor genes, the various cancer-associated mechanisms of these genes
have been elucidated. Relationships of Breast cancer susceptibility gene 1(BRCA1), MutL pro‐
tein homolog 1 (MLH1), and MutS homologue 2 (MSH2), all of which are DNA repair genes
(DNA mismatch repair: MMR), with predispositions to familial cancers have also been
found. Mutation-induced gene inactivation in hereditary cancer is recessively inherited and
many carriers have no abnormal phenotype. However, the cancer prevalence shows marked
dominant inheritance because mutation, inactivation, and loss of heterozygosity readily oc‐
cur in the normal allele [1].
Methylation of RB was the first reported cancer-inducing epimutation [19-20]. Later, methyl‐
ation of many other oncogenes, such as Von Hippel-Lindau (VHL), MLH1, APC, and BRCA1,
was shown in sporadic cancers [22-24]. VHL mutation is related to primary ciliary function,
hemostasis of the extracellular matrix, tumor metabolism, and particularly to clear cell carci‐
noma [25]. Vaziri et al. examined the VHL gene in an analysis of the clonal relationship be‐
tween the primary tumor and metastatic lesions of clear cell carcinoma in 10 patients. The
gene status differed between the primary tumor and the metastatic lesions in 4 patients. In
addition, even when the VHL genotype differed in another renal primary tumor or among
several metastatic lesions within a patient, the VHL germline genotype in adjacent normal
tissue was always the wild-type germline VHL gene in the primary tumor. These findings
indicated that the status of VHL may differ between the primary tumor and metastatic le‐
sions in clear cell carcinoma [26].
Regarding DNA repair genes, methylation of MLH1 and MSH2 has been reported to cause
Lynch syndrome (hereditary non-polyposis colorectal cancer (HNPCC)). This methylation is
also known as a predisposition to characteristic cancers, such as those in the endometrium,
small intestine, and ovary, in addition to colon cancer. Both genes encode mismatch repair
proteins and inactivation of these proteins is thought to induce microsatellite instability
(MSI) in tumors [27]. MSI frequently occurs in endometrial cancer and accumulation of MSI-
induced gene mutations plays a major role in carcinogenesis [28]. It has since been discov‐
ered that MLH1 may also be methylated in sporadic colorectal cancer. In an investigation of
methylation of the MLH1 promoter in 110 patients with sporadic early-onset colorectal can‐
cer, Auclair et al. found methylation in 55 (50%) and also observed decreased MLH1 expres‐
sion due to hypermethylation, which was present in 7.4% of all patients, suggesting that
constitutional epimutation is the fundamental mechanism inducing early-onset colorectal
cancer [29]. The phenotype of sporadic colorectal cancer with MLH1 methylation is the same
as that of mismatch repair defects, and the clinicopathological characteristics are similar to
those of a hereditary tumor. MLH1 methylation occurs in sporadic colorectal cancer at a
high frequency [23] and is strongly related to cancers showing the CpG island methylator
phenotype (CIMP). Methylation of CpG islands, which are characteristic of promoter re‐
gions, has been shown to occur at a high frequency in CIMP-positive cancer [30]. These can‐
cers arise mainly from the ascending colon and have a particularly high incidence in elderly
women.
Gazzoli et al. first demonstrated that MLH1 may be methylated in peripheral blood, as in
tumors, in colorectal cancer patients [31]. In an investigation of 14 Lynch syndrome patients
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with MSI, no mismatch repair gene methylation was noted in any patient, but hypermethy‐
lation (about 50%) of MLH1 was discovered in normal blood DNA in a 25-year-old female
patient [31]. This allelic methylation in unrelated tissue derived from the embryologically
different germ layer indicated that the methylation may be constitutional or germline. No
conclusion could be reached with regard to the heredity of this epimutation because no mu‐
tation was detected in parental tissue, but the occurrence of methylation so early in life is of
interest. A later study clarified that constitutional methylation occurs in colorectal cancer pa‐
tients with hemiallelic methylation of MLH1 [32], in 2 colorectal cancer patients. Tissues
from parents were unavailable, but no methylation was observed in tissues in 4 of 5 children
of these patients.
It remains unclear whether constitutional epimutation is transmitted from the mother or fa‐
ther or occurs de novo in early embryogenesis [1]. Crepin et al. investigated constitutional ep‐
imutations of MLH1 and MSH2 and defective EPCAM in 134 germline mutation-free
patients with suspected Lynch syndrome, and found MLH1 constitutional epimutation in 2
patients. One was a female patient, and her 2 children (one male and one female) developed
early-onset colorectal cancer, suggesting that MLH1 constitutional epimutation is related to
inheritance. In addition, somatic cell BRAF mutation was found in one child, indicating that
cancers in patients with MLH1 constitutional epimutation are similar to MSI-high sporadic
cancers [33]. In addition to reports supporting inheritance from the mother, Goel et al. de‐
scribed cases of epimutation of the paternal allele, in which analysis of the genotype showed
that the inactivated T allele was inherited from the father [34]. Miyukura et al. showed that
complete methylation of the MLH1 promoter region plays an important role in inactivation
of MLH1 in sporadic colorectal cancer patients with high MSI [35]. This complete methyla‐
tion was induced in both alleles, and methylation upstream of the MLH1 promoter region
was also observed in normal large intestinal mucosa adjacent to the cancer in one-third of
colorectal cancer patients with complete methylation [36]. Subsequently, Miyukura et al.
surveyed methylation of the MLH1 promoter region in peripheral blood lymphocytes in 30
patients with sporadic early-onset colorectal cancer or multiple primary cancers, and found
complete methylation of the MLH1 promoter region in peripheral blood lymphocytes (PBLs)
in 4 patients (early-onset sporadic colorectal cancer: 2, multiple cancers including colorectal
cancer: 1, multiple cancers including cancer of the uterine body: 1) [37]. This was hemiallelic
methylation. In one of the patients with early-onset sporadic colorectal cancer, no methyla‐
tion was detected in a sister’s PBLs. MSI was confirmed in all patients and methylation was
also observed in the normal large intestine, gastrointestinal mucosa, endometrium, and bone
marrow in 3. Interestingly, loss of heterozygosity (LOH), loss of the G allele of the MLH1
locus in somatic cells, and biallelic methylation were observed when both alleles of MLH1 in
colorectal cancer were investigated, and these findings are consistent with the germline epi‐
mutation-associated cancerization mechanism based on Knudsen’s “two hit” hypothesis
proposed by Suter et al. (Figure 1) [31]. Furthermore, according to Kantelinen et al., variants
of uncertain significance (VUS) of the mature hereditary MMR gene present in some colorec‐
tal cancer patients may form pairs with other MMR gene VUS and indirectly induce MMR
deficiency. An analysis of 8 pairs of MMR gene mutations carried by cancer patients showed
aberrations in 2 pairs. Pairs with MSH2 may increase the cancer risk by reducing the repair
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ability of the wild-type MSH2 by half. Two MSH6 mutations were MMR defects [38]. MLH1
VUS has also been reported to influence mRNA transcription and impair MMR activity [39].
Figure 1. Mechanisms of epimutation in induction of cancer. (A) Germ cell mutation of tumor suppressor genes. (B)
Germ cell epimutation of tumor suppressor genes. Somatic cell mutation, heterozygote loss, and other allele epimuta‐
tions are triggers that induce tumorigenesis.
Allelic methylation is noted in many cases of Lynch syndrome, but there are some excep‐
tions. Wu et al. investigated germline methylation of MLH1 in 140 gastric cancer patients
with a familial medical history. MLH1 promoter methylation was detected in peripheral
blood DNA in only 0.7% of the gastric cancer patients, and the methylation pattern of these
patients was mosaic. Mosaic germline epimutation of MLH1 occurs in familial gastric can‐
cer, although the incidence is low [40]. Hitchins et al. found allelic MLH1 epimutation in 2
cases in an investigation of constitutional MLH1 methylation in white blood cell DNA in 122
ethnically diverse South African subjects aged ≤50 years old with early-onset colorectal can‐
cer, with a few alleles showing a mosaic pattern [41].
Epimutation is not always inherited and inheritance patterns that do not follow Mendel’s
laws have been reported [5-8]. Complete elimination of epimutation in spermatogenesis has
also been shown. Only inheritance of maternal epimutation has been found in previous re‐
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ports, suggesting that elimination of epimutation in oogenesis is less likely to occur [8-9]. In
a cohort study of 160 Lynch syndrome patients without germline mutation of mismatch re‐
pair genes, constitutive MLH1 methylation was induced in only one patient, and no MLH1
methylation was found in the parents or siblings of this patient, indicating that clinicopatho‐
logical characteristics are better indices than familial medical history for identification of
constitutional epimutation of tumor suppressor genes in cancer patients [5]. In addition,
Pineda et al. reported that it is useful to screen for MLH1 methylation in lymphocyte DNA
in patients with Lynch syndrome-related tumor with early MLH1 methylation to judge the
presence of epimutation [42].
Epimutation is also related to chronic lymphocytic leukemia (CLL), in which apoptosis of
leukemia cells is strongly inhibited. Apoptosis inhibition in CLL is caused by enhanced B-
cell lymphoma 2 (BCL2) production and methylation of the Death-associated protein kinase1
(DAPK1) promoter region [44]. DAPK1 was identified as a familial tumor suppressor gene
and the DAPK1 promoter region is methylated in CLL [44]. This methylation increases Ho‐
meobox B7 (HOXB7) protein binding upstream of the promoter region and 75% of DAPK1
genes in the allele are downregulated. Methylation-induced DAPK1 inactivation causes both
familial and sporadic CLL, whereas hypomethylation of DAPK1 in peripheral blood mono‐
nuclear cells (PBMCs) of healthy subjects has been reported [45]. An association of this hy‐
pomethylation with CLL has yet to be shown.
A recent study showed that a specific MMR gene is involved in regulation of cellular dy‐
namics, such as apoptosis. Therefore, the action of specific MMR gene expression of MSH2
and MLH1 may also be important in resistance to cytotoxic drugs used in chemotherapy,
such as cisplatin [46]. However, it has also been shown that MMR inactivation is not related
to inherent cisplatin resistance of cells, suggesting that MMR inactivation may have a role in
acquired drug resistance [47]. Involvement of impairment of the MMR pathway in aging of
hematopoietic stem and precursor cells has also been reported. Kenyon et al. investigated
MSI and MMR gene expression in hematopoietic stem, precursor, and colony-forming cells,
and found that there were many CD34(+) precursors with MSI lacking MLH1 expression and
protein in hematopoietic colony-forming cells in subjects aged ≥45 years old, compared to
younger subjects [48].
There have been many reports on the relationship of breast cancer with BRCA1 mutation.
Armes and Lakhani et al. showed that breast cancer arising in patients with germline BRCA1
mutation has histological characteristics such as a high mitotic count and lymphocyte infiltra‐
tion. This morphology is now referred to as the basal-like type, and Foulkes et al. found that
this type accounted for 80-90% of cancers arising in germline BRCA1 mutation carriers [49].
Methylation in the BRCA1 promoter region in sporadic breast cancer was subsequently dis‐
covered [50] and this led to many studies on the association between BRCA1 mutation and
methylation. Under the hypothesis that a sporadic tumor with BRCA1 methylation should be
similar to tumors with BRCA1 mutation if BRCA1 methylation induces tumorigenesis, Cat‐
tear and Morris et al. reported that sporadic tumors with BRCA1 methylation have pathologi‐
cal characteristics similar to those of hereditary breast cancer with BRCA1  mutation [51].
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Hedenfalk et al. also showed that the overall phenotypes of the gene were similar between
the two breast cancer types [52]. Tumors accompanied by BRCA1 methylation have a high
grade, are negative for estrogen and progesterone receptors, and have a high incidence in
young women. These features are referred to as BRCA1-like characteristics. Hedenfalk et al.
also found BRCA1 methylation at high frequencies of 67% in medullary carcinoma and 55%
in mucinous carcinoma, and these histologic types were noted at high frequency in family
lines carrying BRCA1  mutations [52]. Recently, Snell et al.  discovered methylation of the
BRCA1 promoter region in normal tissue of breast cancer patients with the BRCA1-like char‐
acteristic histologic type [53]. No germline mutation of BRCA1 or BRCA2 was detected in
these patients. These findings suggest constitutional epimutation of BRCA1 in breast cancer
patients. It is thought that BRCA1 methylation is the first hit and subsequent deletion of both
BRCA1 genes then leads to the characteristic tumor pathology [1].
MMR gene mutation-induced breast cancer in Lynch syndrome has also recently been de‐
scribed by Buerki et al. [54] in an investigation of 70 unrelated families with Lynch syn‐
drome. The subjects were 632 females, of whom 51 and 40 carried MLH1 and MSH2
mutations, respectively. MMR impairment was detected in 85.7% (6/7) of molecular test-ap‐
plicable breast cancer patients. Combined with information from related reports, MSI was
present in 70.3% (26/37) of breast cancer patients with MLH1 or MSH2 mutation, and altered
MMR protein expression was noted in 72.7% (16/22) [54]. Lotsair et al. also found that the
ratio of breast cancer cases with MMR protein deficiency and MSI-induced MMR impair‐
ment was markedly higher in MMR mutant cases than in a non-mutant group. These find‐
ings suggest that MMR dysfunction is closely related to the development of breast cancer in
Lynch syndrome. However, the development pattern and onset age of breast cancer in pa‐
tients with MMR mutation are similar to those in general breast cancer patients without mu‐
tation. Moreover, the frequency of MMR protein deficiency is lower than those in other
Lynch syndrome-related cancers [55].
5. Epimutation and Lynch syndrome
Lynch syndrome (HNPCC) is a typical familial tumor transmitted through autosomal domi‐
nant inheritance, and is observed in about 3% of cases of colorectal cancer [56]. MMR gene
aberration is involved in carcinogenesis in Lynch syndrome. Six types of MMR genes have
been cloned: MSH2, MLH1, MutS protein homolog 3 (MSH3), MutS protein homolog 6 (MSH6),
Postmeiotic segregation increased 1 (PMS1), and Postmeiotic segregation increased 1 (PMS2). Mu‐
tations of 3 of these genes (MSH2, MLH1, and MSH6) in family lines with Lynch syndrome
have been reported [57], with MSH2 and MLH1 aberrations accounting for about 90%, and
MSH6 and PMS2 gene aberrations accounted for only 7 and 1% of cases, respectively [57].
Thus, MLH1 and MSH2 mutations are particularly associated with Lynch syndrome. These
mutations are also predispositions to cancers in the endometrium, small intestine, and ovary
[1]. Both genes encode mismatch repair proteins, and inactivation of these proteins is
thought to induce MSI in tumors [27]. Since microsatellites (short-tandem repeats, STRs) are
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generally present in non-coding regions, mutations in STRs do not lead to abnormal protein
production. However, some STRs are present in regions with important genes, such as those
encoding BCL2-associated X protein (BAX), which is involved in apoptosis induction, Insulin-
like growth factor 2 receptor (IGF2R), which is associated with inhibition of cell proliferation,
and mutations in these regions are thought to be involved in cancerization of cells [1].
Typical cases of Lynch syndrome-related ovarian cancer develop early, and the tumor is
FIGO cancer stage I and non-serous in many cases [58]. Grindedal et al. reported that the
prognosis of Lynch syndrome-related invasive ovarian cancer is better than that of invasive
cancer in patients carrying a BRCA1/2 mutation [59]. Regarding endometrial cancer, Shih et
al. investigated MMR protein deficiency in 56 women aged ≤40 years old with endometrial
cancer, and found abnormal MMR in 9 cases. The families of these 9 patients had a medical
history of Lynch syndrome; the mean BMIs were 23.4 and 31.2 in the patients with and with‐
out abnormal MMR, respectively; the stage was I in 80% of the cases in the patients without
abnormal MMR, but ≥II in 90% of those with abnormal MMR; muscular layer and lymph
vascular invasions were noted in many cases with abnormal MMR; and the 5-year/5-year ex‐
acerbation-free survival rate was 70% [60]. Many pathological aspects of familial endometri‐
al cancer are unclear despite the high malignancy, and an effective screening method has yet
to be established.
Lynch syndrome cases with epimutation of the MLH1 or MSH2 promoter region in blood
cells without morbid MMR gene mutation have recently been discovered, showing that
germline MLH1 epimutation causes Lynch syndrome. Takahashi et al. reported that MLH1
protein expression was deficient in Lynch syndrome patients carrying a germline mutation
in the 5΄ splice site of MLH1, and that mutation of this intron of MLH1 induced aberrant
splicing, influencing the onset of Lynch syndrome [62]. In family lines with MSH2 methyla‐
tion, germline mutation of the Epithelial cell adhesion molecule (EPCAM) gene present up‐
stream of MSH2 has been reported to be the cause of epimutation. EPCAM is strongly
expressed in epithelial tissue and cancers [63] and a defective 3΄-terminal of this gene causes
read-through to MSH2, resulting in hypermethylation of the CpG island promoter [64]. In‐
terestingly, no MSH2 methylation in any other cancer has been reported to date. In contrast
to the allelic methylation found in many patients with constitutional methylation of MLH1,
allelic methylation of MSH2 occurs in only about 50%. This methylation level is also de‐
pendent on the tissues examined. Unlike MLH1 epimutation, inheritance of MSH2 methyla‐
tion following Mendel’s laws has been reported. In Lynch syndrome caused by these
epimutations, methylation levels vary among epimutation carriers in the same family line
and among tissues within the same patient [1]. In addition, the MLH1 and MSH2 mutations
show racial differences. In a comparison of Asian and Western subjects based on Interna‐
tional Society of Gastrointestinal Hereditary (InSiGHT) data, Wei et al. found differences in
mutations in the regions containing MLH1 and MSH2, with some mutations found to be
more frequent or to be present only in Asian subjects [65]. This indicates the importance of
consideration of racial differences in evaluating mutations in screening [65].
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6. Conclusion
Epimutation has diverse characteristics: some epimutations are inherited or eliminated in
embryogenesis, while others are inherited in patterns that do not follow Mendel’s laws.
Cancers associated with epimutations include Lynch syndrome (HNPCC), familial colorec‐
tal cancer, CLL, breast cancer, and ovarian cancer. Defined histological characteristics of epi‐
mutation-associated tumors have been suggested, and it is possible that the histologic type
of cancers will ultimately be identifiable based on the methylation pattern detected in nor‐
mal tissue, which may reduce the need for invasive tests such as tumor tissue biopsy [1].
Furthermore, elucidation of differences in the methylation pattern between healthy subjects
and cancer patients may facilitate low-invasive cancer risk evaluation in healthy individuals.
To develop these techniques, it will be important to identify the causes of methylation. The
extent of variation of methylation in normal somatic cell tissues within an individual is un‐
clear, but conservation of the methylation pattern in an individual has been shown [1]. Dif‐
ferent DNA methylation patterns in monozygotic twins have been observed, and the
difference increased as the twins lived in different environments [66]. Aging-dependent
methylation of non-methylated CpG islands has also been shown, and it has been suggested
that metabolite ingestion can influence methyl metabolism, such as metabolism of folic acid,
choline, vitamin B12, and betaine, and change the methylation pattern. In particular, the in‐
fluence of environmental factors in early embryogenesis may serve as a predisposition to
cancers and other diseases associated with epigenetic changes [67]. Methylation is influ‐
enced by environmental factors and aging, in addition to inheritance, as described above,
and further studies on the association of these factors with epimutation are required.
Improvement of epigenetic aberration has also been attempted through induction of re-ex‐
pression of tumor suppressor genes, with some success using DNA methyltransferase
(DNMT) inhibitors, azacitidine and decitabine, for blood malignant tumors [68]. However,
intense epigenetic therapy using a DNMT inhibitor and a histone deacetylase (HDAC) in‐
hibitor concomitantly did not achieve complete chromosome remodeling, and stable gene
re-expression was not obtained [9]. Moreover, reinhibition of re-expressed genes has occur‐
red after suspension of epigenetic therapy in many studies. These findings indicate that
there are many problems to be overcome in development of epigenetic therapy.
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